Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1997 Aug;63(2):204–209. doi: 10.1136/jnnp.63.2.204

Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity

B Middel 1, H Kuipers-Upmeijer 1, J Bouma 1, M Staal 1, D Oenema 1, T Postma 1, S Terpstra 1, R Stewart 1
PMCID: PMC2169658  PMID: 9285459

Abstract

OBJECTIVES—To compare clinical effectiveness and health related quality of life in patients with severe spasticity who received intrathecal baclofen or a placebo.
METHODS—In a double blind, randomised, multicentre trial 22 patients were followed up during 13 weeks and subsequently included in a 52 week observational longitudinal study. Patients were those with chronic, disabling spasticity who did not respond to maximum doses of oral baclofen, dantrolene, and tizanidine. After implantation of a programmable pump patients were randomly assigned to placebo or baclofen infusion for 13 weeks. After 13 weeks all patients received baclofen. Clinical efficacy was assessed by the Ashworth scale, spasm score, and self reported pain, and health related quality of life by the sickness impact profile (SIP) and the Hopkins symptom checklist (HSCL).
RESULTS—At three months the scores of the placebo and baclofen group differed slightly for the spasm score (effect size=0.20) and substantially for the Ashworth scale (effect size=1.40) and pain score (effect size=0.94); health related quality of life showed no significant differences. Three months after implantation the baclofen group showed a significant, substantial improvement on the SIP "physical health", "mental health", "mobility", and "sleep and rest" subscales and on the HSCL mental health scale; patients receiving placebo showed no change. After one year of baclofen treatment significant (P<0.05) improvement was found on the SIP dimensions "mobility" and "body care and movement" with moderate effect sizes. Improvement on the SIP subscale "physical health" (P<0.05; effect size 0.86), the SIP overall score (without "ambulation"), and the "physical health" and overall scale of the HSCL was also significant, with effect sizes >0.80. Changes in health related behaviour were noted for "sleep and rest" and "recreation and pastimes" (P<0.01, P<0.05; effect size 0.95 and 0.63, respectively). Psychosocial behaviour showed no improvement.
CONCLUSIONS—Intrathecal baclofen delivered by an implanted, programmable pump resulted in improved self reported quality of life as assessed by the SIP, and HSCL physical health dimensions also suggest improvement.



Full Text

The Full Text of this article is available as a PDF (135.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ASHWORTH B. PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS. Practitioner. 1964 Apr;192:540–542. [PubMed] [Google Scholar]
  2. Azouvi P., Mane M., Thiebaut J. B., Denys P., Remy-Neris O., Bussel B. Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up. Arch Phys Med Rehabil. 1996 Jan;77(1):35–39. doi: 10.1016/s0003-9993(96)90217-8. [DOI] [PubMed] [Google Scholar]
  3. Bergner M., Bobbitt R. A., Carter W. B., Gilson B. S. The Sickness Impact Profile: development and final revision of a health status measure. Med Care. 1981 Aug;19(8):787–805. doi: 10.1097/00005650-198108000-00001. [DOI] [PubMed] [Google Scholar]
  4. Coffey J. R., Cahill D., Steers W., Park T. S., Ordia J., Meythaler J., Herman R., Shetter A. G., Levy R., Gill B. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg. 1993 Feb;78(2):226–232. doi: 10.3171/jns.1993.78.2.0226. [DOI] [PubMed] [Google Scholar]
  5. Hugenholtz H., Nelson R. F., Dehoux E., Bickerton R. Intrathecal baclofen for intractable spinal spasticity--a double-blind cross-over comparison with placebo in 6 patients. Can J Neurol Sci. 1992 May;19(2):188–195. [PubMed] [Google Scholar]
  6. Loubser P. G., Narayan R. K., Sandin K. J., Donovan W. H., Russell K. D. Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury. Paraplegia. 1991 Jan;29(1):48–64. doi: 10.1038/sc.1991.7. [DOI] [PubMed] [Google Scholar]
  7. McLean B. N. Intrathecal baclofen in severe spasticity. 1993 Feb 17-Mar 2Br J Hosp Med. 49(4):262–267. [PubMed] [Google Scholar]
  8. Meythaler J. M., Steers W. D., Tuel S. M., Cross L. L., Haworth C. S. Continuous intrathecal baclofen in spinal cord spasticity. A prospective study. Am J Phys Med Rehabil. 1992 Dec;71(6):321–327. doi: 10.1097/00002060-199212000-00003. [DOI] [PubMed] [Google Scholar]
  9. Nance P., Schryvers O., Schmidt B., Dubo H., Loveridge B., Fewer D. Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions. Can J Neurol Sci. 1995 Feb;22(1):22–29. doi: 10.1017/s0317167100040452. [DOI] [PubMed] [Google Scholar]
  10. Patterson V., Watt M., Byrnes D., Crowe D., Lee A. Management of severe spasticity with intrathecal baclofen delivered by a manually operated pump. J Neurol Neurosurg Psychiatry. 1994 May;57(5):582–585. doi: 10.1136/jnnp.57.5.582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Penn R. D. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg. 1992 Aug;77(2):236–240. doi: 10.3171/jns.1992.77.2.0236. [DOI] [PubMed] [Google Scholar]
  12. Saltuari L., Kronenberg M., Marosi M. J., Kofler M., Russegger L., Rifici C., Bramanti P., Gerstenbrand F. Indication, efficiency and complications of intrathecal pump supported baclofen treatment in spinal spasticity. Acta Neurol (Napoli) 1992 Jun;14(3):187–194. [PubMed] [Google Scholar]
  13. Steinbok P., Daneshvar H., Evans D., Kestle J. R. Cost analysis of continuous intrathecal baclofen versus selective functional posterior rhizotomy in the treatment of spastic quadriplegia associated with cerebral palsy. Pediatr Neurosurg. 1995;22(5):255–265. doi: 10.1159/000120911. [DOI] [PubMed] [Google Scholar]
  14. Teddy P., Jamous A., Gardner B., Wang D., Silver J. Complications of intrathecal baclofen delivery. Br J Neurosurg. 1992;6(2):115–118. doi: 10.3109/02688699209002912. [DOI] [PubMed] [Google Scholar]
  15. Zielhuis G. A., Straatman H., van 't Hof-Grootenboer A. E., van Lier H. J., Rach G. H., van den Broek P. The choice of a balanced allocation method for a clinical trial in otitis media with effusion. Stat Med. 1990 Mar;9(3):237–246. doi: 10.1002/sim.4780090306. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES